Go Pro
→ How Long Does $2.5M Last in Retirement? (From SmartAsset) (Ad)tc pixel Free GXAI Stock Alerts

Gaxos.ai (GXAI) Competitors

Gaxos.ai logo
$0.77 +0.01 (+0.92%)
As of 10:13 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

GXAI vs. MGRX, AIDX, BMGL, NIVF, and BIAF

Should you buy Gaxos.ai stock or one of its competitors? Gaxos.ai's main competitors and comparable companies include Mangoceuticals (MGRX), 20/20 Biolabs (AIDX), Basel Medical Group (BMGL), NewGenIvf Group (NIVF), and bioAffinity Technologies (BIAF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Gaxos.ai compare to Mangoceuticals?

Mangoceuticals (NASDAQ:MGRX) and Gaxos.ai (NASDAQ:GXAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Gaxos.ai has higher revenue and earnings than Mangoceuticals. Gaxos.ai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mangoceuticals$460K18.05-$20.64M-$1.01N/A
Gaxos.ai$1.93M2.82-$3.90M-$0.50N/A

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 42.6% of Gaxos.ai shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Comparatively, 3.2% of Gaxos.ai shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Mangoceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, Gaxos.ai has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

In the previous week, Mangoceuticals' average media sentiment score of 0.00 equaled Gaxos.ai'saverage media sentiment score.

Company Overall Sentiment
Mangoceuticals Neutral
Gaxos.ai Neutral

Gaxos.ai has a net margin of -64.81% compared to Mangoceuticals' net margin of -4,794.60%. Gaxos.ai's return on equity of -38.79% beat Mangoceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mangoceuticals-4,794.60% -96.39% -89.60%
Gaxos.ai -64.81%-38.79%-36.99%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mangoceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Gaxos.ai
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Gaxos.ai beats Mangoceuticals on 6 of the 11 factors compared between the two stocks.

How does Gaxos.ai compare to 20/20 Biolabs?

Gaxos.ai (NASDAQ:GXAI) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

42.6% of Gaxos.ai shares are held by institutional investors. 3.2% of Gaxos.ai shares are held by company insiders. Comparatively, 29.8% of 20/20 Biolabs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

20/20 Biolabs has higher revenue and earnings than Gaxos.ai. Gaxos.ai is trading at a lower price-to-earnings ratio than 20/20 Biolabs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gaxos.ai$1.93M2.82-$3.90M-$0.50N/A
20/20 Biolabs$2.05M3.85-$3.74M-$0.54N/A

In the previous week, 20/20 Biolabs had 1 more articles in the media than Gaxos.ai. MarketBeat recorded 1 mentions for 20/20 Biolabs and 0 mentions for Gaxos.ai. Gaxos.ai's average media sentiment score of 0.00 equaled 20/20 Biolabs'average media sentiment score.

Company Overall Sentiment
Gaxos.ai Neutral
20/20 Biolabs Neutral

20/20 Biolabs has a consensus target price of $5.00, suggesting a potential upside of 709.06%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts clearly believe 20/20 Biolabs is more favorable than Gaxos.ai.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gaxos.ai
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

20/20 Biolabs has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. 20/20 Biolabs' return on equity of 0.00% beat Gaxos.ai's return on equity.

Company Net Margins Return on Equity Return on Assets
Gaxos.ai-64.81% -38.79% -36.99%
20/20 Biolabs N/A N/A N/A

Summary

20/20 Biolabs beats Gaxos.ai on 12 of the 14 factors compared between the two stocks.

How does Gaxos.ai compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and Gaxos.ai (NASDAQ:GXAI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Basel Medical Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Gaxos.ai
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Basel Medical Group has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, Gaxos.ai has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

In the previous week, Basel Medical Group had 1 more articles in the media than Gaxos.ai. MarketBeat recorded 1 mentions for Basel Medical Group and 0 mentions for Gaxos.ai. Basel Medical Group's average media sentiment score of 1.14 beat Gaxos.ai's score of 0.00 indicating that Basel Medical Group is being referred to more favorably in the media.

Company Overall Sentiment
Basel Medical Group Positive
Gaxos.ai Neutral

42.6% of Gaxos.ai shares are held by institutional investors. 3.2% of Gaxos.ai shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Basel Medical Group has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. Basel Medical Group's return on equity of 0.00% beat Gaxos.ai's return on equity.

Company Net Margins Return on Equity Return on Assets
Basel Medical GroupN/A N/A N/A
Gaxos.ai -64.81%-38.79%-36.99%

Gaxos.ai has lower revenue, but higher earnings than Basel Medical Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Basel Medical Group$8.90M0.85-$9.50MN/AN/A
Gaxos.ai$1.93M2.82-$3.90M-$0.50N/A

Summary

Basel Medical Group beats Gaxos.ai on 6 of the 11 factors compared between the two stocks.

How does Gaxos.ai compare to NewGenIvf Group?

NewGenIvf Group (NASDAQ:NIVF) and Gaxos.ai (NASDAQ:GXAI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

66.2% of NewGenIvf Group shares are owned by institutional investors. Comparatively, 42.6% of Gaxos.ai shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by insiders. Comparatively, 3.2% of Gaxos.ai shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, NewGenIvf Group had 7 more articles in the media than Gaxos.ai. MarketBeat recorded 7 mentions for NewGenIvf Group and 0 mentions for Gaxos.ai. NewGenIvf Group's average media sentiment score of 1.65 beat Gaxos.ai's score of 0.00 indicating that NewGenIvf Group is being referred to more favorably in the media.

Company Overall Sentiment
NewGenIvf Group Very Positive
Gaxos.ai Neutral

NewGenIvf Group has higher revenue and earnings than Gaxos.ai.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewGenIvf Group$4.73M0.47$9.88MN/AN/A
Gaxos.ai$1.93M2.82-$3.90M-$0.50N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewGenIvf Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Gaxos.ai
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

NewGenIvf Group has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market. Comparatively, Gaxos.ai has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

NewGenIvf Group has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. NewGenIvf Group's return on equity of 0.00% beat Gaxos.ai's return on equity.

Company Net Margins Return on Equity Return on Assets
NewGenIvf GroupN/A N/A N/A
Gaxos.ai -64.81%-38.79%-36.99%

Summary

NewGenIvf Group beats Gaxos.ai on 9 of the 11 factors compared between the two stocks.

How does Gaxos.ai compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAF) and Gaxos.ai (NASDAQ:GXAI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Gaxos.ai has a net margin of -64.81% compared to bioAffinity Technologies' net margin of -257.30%. Gaxos.ai's return on equity of -38.79% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
bioAffinity Technologies-257.30% -220.52% -136.76%
Gaxos.ai -64.81%-38.79%-36.99%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
bioAffinity Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Gaxos.ai
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 42.6% of Gaxos.ai shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by insiders. Comparatively, 3.2% of Gaxos.ai shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, bioAffinity Technologies had 7 more articles in the media than Gaxos.ai. MarketBeat recorded 7 mentions for bioAffinity Technologies and 0 mentions for Gaxos.ai. Gaxos.ai's average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.43 indicating that Gaxos.ai is being referred to more favorably in the news media.

Company Overall Sentiment
bioAffinity Technologies Neutral
Gaxos.ai Neutral

Gaxos.ai has lower revenue, but higher earnings than bioAffinity Technologies. Gaxos.ai is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$6.16M1.08-$14.91M-$109.45N/A
Gaxos.ai$1.93M2.82-$3.90M-$0.50N/A

bioAffinity Technologies has a beta of -1.11, meaning that its share price is 211% less volatile than the broader market. Comparatively, Gaxos.ai has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Summary

Gaxos.ai beats bioAffinity Technologies on 10 of the 13 factors compared between the two stocks.

Get Gaxos.ai News Delivered to You Automatically

Sign up to receive the latest news and ratings for GXAI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GXAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GXAI vs. The Competition

Export
MetricGaxos.aiHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5.45M$9.97B$7.26B$12.73B
Dividend YieldN/A2.56%2.53%8.56%
P/E Ratio-1.5334.83273.3125.25
Price / Sales2.824.88622.1298.12
Price / CashN/A120.9077.8252.26
Price / Book0.333.9813.086.14
Net Income-$3.90M$310.54M$3.47B$349.01M
7 Day Performance-1.85%0.74%0.52%-0.31%
1 Month Performance-15.66%0.11%5.63%0.64%
1 Year Performance-50.96%15.75%25.31%14.83%

Gaxos.ai Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GXAI
Gaxos.ai
0.3178 of 5 stars		$0.77
+0.9%		N/A-54.0%$5.48M$1.93MN/A3
MGRX
Mangoceuticals
0.4811 of 5 stars		$0.38
-1.8%		N/A-82.3%$8.28M$460KN/A3
AIDX
20/20 Biolabs
2.0938 of 5 stars		$0.63
+2.4%		$5.00
+693.1%		N/A$8.05M$2.04MN/A14
BMGL
Basel Medical Group
0.9655 of 5 stars		$4.90
-3.6%		N/A-79.8%$7.64M$8.90MN/A36
NIVF
NewGenIvf Group
2.4943 of 5 stars		$1.21
-9.0%		N/A-99.9%$7.16M$4.73MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GXAI) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Earth's biggest energy source: near Grand Canyon
The largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...
Behind the Markets | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel
Why Boston Ships In Natural Gas It Already Has at Home
A tanker called the Iberica Knutsen once sailed 2,272 miles from Trinidad and Tobago to deliver liquefied natu...
Porter & Company | Sponsoredtc pixel